Tag: AML
BVX001 is Well-tolerated in Preclinical Study – Demonstrating a Favorable Safety...
Results from a preclinical toxicity evaluation study with BVX001, a novel antibody-drug conjugates (ADC) being developed by BiVictriX, showed positive in vivo data when compared to gemtuzumab ozogamicin (Mylotarg™; Pfizer).
Magenta Therapeutics Halts Phase 1/2 Dose Escalation Trial of Conditioning ADC...
Magenta Therapeutics Halts Phase 1/2 Dose Escalation Trial of Conditioning ADC MGTA-117
Study Reinforces the Potential of Pivekimab Sunirine as a Novel Addition...
Initial safety and efficacy findings from an open-label, dose-escalation and expansion cohorts of the Phase 1b/2 study of pivekimab sunirine (IMGN632), a CD123 (Interleukin-3 alpha...
Researchers Complete Enrollment in Phase 3 SIERRA Trial of Iomab-B
Enrollment of the Phase 3 SIERRA trial of the Antibody-radiation Conjugate (ARC) 131I apamistamab (Iomab-B), being developed by Actinium Pharmaceuticals, has been completed.
Iomab-B includes...
ASH 2020: Preclinical Models Identify CD74 as Potential Target for the...
Presentations during the virtual 62nd American Society of Hematology (ASH) Annual Meeting for the ongoing Phase 1 dose-escalation clinical trial with STRO-001, a CD74-targeted...
Institutional Review Board Approves Phase I Trial with GTB-3550
The University of Minnesota's Institutional Review Board (IRB) and Cancer Protocol Review Committee (CPRC) has granted GT Biopharma (Westlake Village, CA 91362), permission to...
Merus Therpeutics: Seeking to Advance Immuno-Oncology
In Oncology, many new developments of the last decade have made it possible to treat cancers in ways that are better-targeted, more potent, and...
Independent Data Monitoring Committee Recommends Pivotal Phase III SIERRA Trial Continue...
Independent Data Monitoring Committee (DMC) for the Pivotal Phase III SIERRA Trial (Study of Iomab-B for Elderly Relapsed or Refractory AML) of Iomab-B (131I...
IMGN779 Demonstrates Favorable Safety Profile with repeat Dosing and no Dose-limiting...
The first-in-human data demonstrate the safety and tolerability of IMGN779, being developed by ImmunoGen, across seven dose levels, with no dose limiting toxicities (DLTs),...
Pfizer Resubmits Application for Gemtuzumab Ozogamicin to European and American Regulators
In late January 2017 Pfizer's Biologics License Application (BLA) for gemtuzumab ozogamicin (Mylotarg®; previously known as CMA-676) was accepted for filing by the U.S....
